Remarkable Images Reveal the Effects of Common Antibiotics on E. coli

The above image displays untreated E. coli bacteria, with the lower image showing the effects of polymyxin B after 90 minutes.

Carolina Borrelli, Edward Douglas et al./Nature Microbiology

High-resolution microscopy unveils how polymyxins, a class of antibiotics, penetrate bacterial defenses, offering insights for developing treatments against drug-resistant infections.

Polymyxins serve as a last-resort option for treating Gram-negative bacteria responsible for serious infections like pneumonia, meningitis, and typhoid fever. “The priority pathogens identified by the top three health agencies globally are predominantly Gram-negative bacteria, highlighting their complex cell envelopes,” states Andrew Edwards from Imperial College London.

These bacteria possess an outer layer of lipopolysaccharides that functions as armor. While it was known that polymyxins target this layer, the mechanisms of their action and the reasons for inconsistent effectiveness remained unclear.

In a pivotal study, Edwards and his team employed biochemical experiments combined with nuclear power microscopy, capturing details at the nanoscale. They discovered that polymyxin B, amongst other treatments, actively targets E. coli cells.

Shortly after treatment commenced, the bacteria rapidly began releasing lipopolysaccharides.

Researchers observed that the presence of antibiotics prompted bacteria to attempt to assimilate more lipopolysaccharide “bricks” into their protective walls. However, this effort resulted in gaps, allowing antibiotics to penetrate and destroy the bacteria.

“Antibiotics are likened to tools that aid in the removal of these ‘bricks’,” Edwards explains. “While the outer membrane doesn’t entirely collapse, gaps appear, providing an entryway for antibiotics to access the internal membrane.”

The findings also elucidate why antibiotics occasionally fail: they predominantly affect active, growing bacteria. When in a dormant state, polymyxin B becomes ineffective as these bacteria do not produce armor strong enough to withstand environmental pressures.

E. coli images exposed to polymyxin B illustrate changes to the outer membrane over time: untreated, 15 mins, 30 mins, 60 mins, and 90 mins.

Carolina Borrelli, Edward Douglas et al./Nature Microbiology

Interestingly, researchers found that introducing sugar to E. coli could awaken dormant cells, prompting armor production to resume within 15 minutes, leading to cell destruction. This phenomenon is thought to be applicable to other polymyxins, such as polymyxin E, used therapeutically.

Edwards proposes that targeting dormant bacteria with sugar might be feasible, though it poses the risk of hastening their growth. “We don’t want bacteria at infection sites rapidly proliferating due to this stimulation,” he cautions. Instead, he advocates for the potential to combine various drugs to bypass dormancy without reactivating the bacteria.

topic:

Source: www.newscientist.com

The E. coli Genome Redesigned with 101,000 DNA Modifications

E. coli can lead to serious illnesses, yet is frequently utilized in pharmaceutical development.

Victor Habbick Visions/Science Photo Library

Unlike the natural evolution of life forms, our ability to create life has reached new heights. The genome of an E. coli bacterium has been meticulously redesigned via computer simulations, utilizing just 57 out of the 64 genetic codons. This synthetic genome was built from the ground up and introduced into living bacterial cells.

“This was a massive undertaking,” states Wesley Robertson from the Institute of Medical Research in Molecular Biology, Cambridge, UK.

The objective was to demonstrate the feasibility of this approach, with the 57 codons, termed Syn57, offering commercial applications. Future modifications could enable Syn57 to develop complete resistance to viral infections, a significant benefit for the industrial production of proteins used in pharmaceuticals, food, or cosmetics. Since viral proteins depend on their hosts to produce, altering the genetic code can lead to erroneous viral proteins.

Moreover, additional modifications permit Syn57 to synthesize proteins containing up to 27 amino acids, whereas natural proteins are limited to 20. These synthetic proteins hold potential for functions unattainable with conventional proteins.

A protein is essentially a sequence of amino acids arranged in a specified order determined by a gene. Each triplet of DNA bases, known as a codon, instructs the synthesis machinery on when to add the next amino acid or when to cease the protein assembly.

There are four DNA bases that combine to produce 64 distinct codons. However, organisms on Earth typically utilize only 20 amino acids, leading to considerable redundancy, with multiple codons corresponding to each amino acid.

If all instances of a specific codon for an amino acid were substituted with another codon for the same amino acid, that original codon could then be repurposed. For instance, it could code for non-natural amino acids or alternative chemicals, facilitating the creation of novel protein types.

Theoretically, only 21 unique codons are required, allowing for a biological organism to free up to 43 codons—one for each natural amino acid and one stop codon. However, this is not yet feasible, as increasing genetic alterations raises the likelihood of harmful unintended consequences.

Instead, biologists are taking a more measured approach. In 2011, an edit of 314 genes in E. coli aimed to free one codon.

Because executing thousands of genetic edits is so labor-intensive, Robertson and his team opted to synthesize the DNA from scratch. In 2019, they introduced Syn61, incorporating 18,000 changes across 4 million DNA bases, achieving the release of three codons in the E. coli genome. A derivative company named Constructive.Bio is working on commercial applications.

Currently, researchers are implementing 101,000 modifications to release seven codons within Syn57. This process necessitated testing small sections of the reconstructed genome on live bacterial cultures to identify and rectify harmful changes. This complex procedure was repeated with progressively larger genome fragments until the entire structure was reassembled.

“This marks a significant achievement, resulting from years of effort,” mentions Akos Nyerges at Harvard Medical School. Nyerges’ team is also working to release seven codons in E. coli via different codon reproductions. “Our journey with the 57 codons in E. coli is ongoing,” he adds.

While Syn57 is already fully established, its growth rate is significantly slower than that of typical strains. Enhancements in this aspect are essential for commercial viability. “We anticipate being able to improve the growth rates, making it more beneficial,” remarks Robertson.

For the time being, his focus will be on investigating the potential applications of Syn57 rather than attempting further codon releases. “There’s still a great deal to accomplish before contemplating even more compressed genetic codes,” he concludes.

The first synthetic genome bacteria were created in 2010, but their design aimed more at simplifying organisms than at codon recovery.

Topic:

Source: www.newscientist.com